Strong Financial Performance of Catheter Precision
Catheter Precision, Inc. (NYSE American: VTAK), an innovative medical device company dedicated to improving cardiac electrophysiology practices, has recently reported its financial outcomes for the latest quarter and nine months. This announcement marks significant progress and showcases the company's commitment to excellence in the medical field.
Remarkable Revenue Increases
Total revenue for Catheter Precision in the third quarter of 2025 reached $226,000. This figure signifies an impressive rise of 135% compared to the same period last year when revenue was reported at $96,000. Equally encouraging is the overall revenue for the first nine months of 2025, which totaled $581,000, reflecting a 114% increase from $271,000 during the first nine months of 2024. Such performance illustrates substantial growth and an increasing market presence.
Net Loss Reduction
Despite the growth in revenue, the company reported a GAAP net loss of $2,251,000 for Q3 2025, which is a notable reduction of 45% compared to the $4,120,000 loss recorded in Q3 2024. For the nine months ended September 30, the net loss was $11,405,000, slightly up from $11,015,000 the previous year.
Expanding Global Reach
Sales activities for the LockeT suture retention device outside the U.S. are thriving, particularly following its recent CE Mark approval. The device has attracted interest in various countries, including Germany, France, Italy, Spain, Portugal, the UK, and South Africa. Recently, five accounts in South Africa have placed reorders, showcasing the product's growing acceptance in the market.
VIVO Product Line Gains Traction
The sales activity surrounding the VIVO product line is similarly gaining momentum internationally, with significant successes including the first purchase order from France in October. This demonstrates the escalating demand for advanced medical solutions offered by Catheter Precision.
Focus on Clinical Advancements
Catheter Precision places a high priority on clinical studies and the publication of their findings. In late September, an interview with Dr. Luigi Di Biase, a key opinion leader in the electrophysiology field, was featured in a respected publication. In this interview, he highlighted the economic benefits and clinical applications of the LockeT device, reinforcing its role in enhancing patient outcomes during electrophysiological procedures.
Leadership Insights
David Jenkins, the CEO of Catheter Precision, expressed optimism about the company's trajectory: "With our remarkable Q3 results and a robust product pipeline, we are poised for considerable growth in the upcoming year. The successful completion of two VIVO clinical studies further bolsters our confidence that VIVO provides a groundbreaking approach to treating ventricular arrhythmias. We aim to capture a significant share of this important market segment." This forward-looking perspective reflects the strategic ambitions of Catheter Precision.
Commitment to Innovation
Catheter Precision is committed to providing innovative solutions that enhance the treatment of cardiac arrhythmias. By collaborating with healthcare professionals and leveraging cutting-edge technology, the company focuses on refining its products to meet the evolving needs of the healthcare landscape.
About VIVO and LockeT
The VIVO™ system by Catheter Precision is a state-of-the-art non-invasive 3D imaging tool that helps physicians determine the origin of ventricular arrhythmias prior to procedures. This technology not only streamlines operational processes but also significantly reduces procedure times. The system has achieved marketing clearance from the U.S. FDA and holds the CE mark as well, underscoring its credibility and acceptance.
Additionally, the LockeT device enables efficient hemostasis after venous punctures in a procedure. With its Class 1 designation and FDA registration, it exemplifies the high standards Catheter Precision adheres to in its product offerings.
Contact Information for Further Inquiry
For more details regarding Catheter Precision's innovative offerings and results, individuals are encouraged to get in touch with David Jenkins at 973-691-2000 or via email at IR@catheterprecision.com.
Frequently Asked Questions
What is Catheter Precision's core focus?
Catheter Precision specializes in innovative medical devices aimed at improving cardiac electrophysiology treatments.
How much revenue did Catheter Precision report for Q3 2025?
The company reported a revenue of $226,000 for the third quarter of 2025.
What factors contributed to the recent revenue growth?
The increase can be attributed to rising sales of the LockeT and VIVO product lines, especially in international markets.
Who is the CEO of Catheter Precision?
David Jenkins fills the role of CEO at Catheter Precision, leading the company's strategic initiatives.
What is the VIVO product system?
VIVO is a non-invasive imaging system that allows physicians to identify the origins of ventricular arrhythmias pre-procedure, enhancing workflow and reducing procedure times.
